# Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer

> **NCT02323737** · PHASE2 · COMPLETED · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 62 (actual)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Irinotecan and cisplatin
- **DRUG:** Etoposide and cisplatin

## Key facts

- **NCT ID:** NCT02323737
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-06
- **Final completion:** 2012-06
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2014-12-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02323737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02323737, "Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02323737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*